Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol. 2011;25(2):281–90. https://doi.org/10.1016/j.bpg.2011.02.009.

Article  CAS  PubMed  Google Scholar 

Rajapaksha I. Liver fibrosis, liver cancer, and advances in therapeutic approaches. Livers. 2022;2(4):372–86. https://doi.org/10.3390/livers2040028.

Article  Google Scholar 

Lee MJ. A review of liver fibrosis and cirrhosis regression. J Pathol Transl Med. 2023;57(4):189–95. https://doi.org/10.4132/jptm.2023.05.24.

Article  PubMed  PubMed Central  Google Scholar 

Malnick SDH, Alin P, Somin M, Neuman MG. Fatty liver disease-alcoholic and non-alcoholic: similar but different. Int J Mol Sci. 2022;23(24):16226. https://doi.org/10.3390/ijms232416226.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397–411. https://doi.org/10.1038/nrgastro.2017.38.

Article  CAS  PubMed  Google Scholar 

Taru V, Szabo G, Mehal W, Reiberger T. Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation. J Hepatol. 2024;81(5):895–910. https://doi.org/10.1016/j.jhep.2024.06.016.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang K, Lin B. Pathophysiological significance of hepatic apoptosis. ISRN Hepatol. 2013;2013:740149. https://doi.org/10.1155/2013/740149.

Article  CAS  PubMed  Google Scholar 

Guicciardi ME, Gores GJ. Apoptosis as a mechanism for liver disease progression. Semin Liver Dis. 2010;30(4):402–10. https://doi.org/10.1055/s-0030-1267540.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol. 2014;60(5):1063–74. https://doi.org/10.1016/j.jhep.2013.12.026.

Article  CAS  PubMed  Google Scholar 

Sharma S, Carmona A, Skowronek A, Giorgetti E, Spacek M, Barrios-Rodiles M, et al. Apoptotic signalling targets the post-endocytic sorting machinery of the death receptor Fas/CD95. Nat Commun. 2019;10:3105. https://doi.org/10.1038/s41467-019-11025-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang D, Xiao J, Deng X, Ma K, Liao X, Liu C, et al. Association between fas/fasl gene polymorphism and musculoskeletal degenerative diseases: a meta-analysis. BMC Musculoskelet Disord. 2018;19:137. https://doi.org/10.1186/s12891-018-2057-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang Y, Deng D, Li H, Xiao Q, Huang L, Zhang B, et al. Fas-670A > G polymorphism is not associated with an increased risk of acute myeloid leukemia development. Biomed Rep. 2015;4(2):153–60. https://doi.org/10.3892/br.2015.564.

Article  PubMed  PubMed Central  Google Scholar 

Zhao T, Li W, Chen J, Qin W. Genomic variants in Fas-mediated apoptosis pathway predict a poor response to Platinum-based chemotherapy for Chinese gastric cancer patients. J Cancer. 2021;12(3):849–59. https://doi.org/10.7150/jca.48120.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Apaza Alccayhuaman KA, Heimel P, Lee JS, Tangl S, Kuchler U, Marchesan J, et al. FasL is a catabolic factor in alveolar bone homeostasis. J Clin Periodontol. 2022;50(3):396–405. https://doi.org/10.1111/jcpe.13750.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohammadi A, Salehi M, Khanbabaei H, Sheikhesmaeili F, Tajik N, Alavian SM. Fas and FasL promoter polymorphisms and susceptibility to HBV infection: a systematic review and meta-analysis. Infect Genet Evol. 2019;76:104003. https://doi.org/10.1016/j.meegid.2019.104003.

Article  CAS  PubMed  Google Scholar 

Wu J, Tang L, Ma Y, Li Y, Zhang D, Chen H, et al. Association between fas/fasl gene polymorphism and susceptibility to hepatitis B virus infection: a meta-analysis. J Viral Hepat. 2020;27(3):272–85. https://doi.org/10.1111/jvh.13231.

Article  CAS  Google Scholar 

Chen L, Wang X, Liu Q, Zhang S, Shen Y. FasL-844C polymorphism is associated with increased risk of HCV-related liver diseases: A systematic review and meta-analysis. Hepatol Res. 2021;51(4):391–403. https://doi.org/10.1111/hepr.13614.

Article  Google Scholar 

Park JH, Kim SY, Lee MS, Choi DH, Yoon KH, Lee JW. Association between FAS-670A > G polymorphism and susceptibility to alcoholic liver disease: a case-control study. J Hepatol Res. 2021;46(3):578–89. https://doi.org/10.1016/j.jhepres.2021.02.018.

Article  Google Scholar 

Kumar A, Singh V, Patel RK, Sharma S, Agarwal N. The FASL-844T > C polymorphism predicts severity in alcoholic hepatitis: implications for targeted therapy. Liver Int. 2020;40(5):1142–53. https://doi.org/10.1111/liv.2020.40.issue-5.24.

Article  Google Scholar 

Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer—pilot study of 134 cases. PLoS ONE. 2012;7(9):e44559. https://doi.org/10.1371/journal.pone.0044559.

Article  CAS  Google Scholar 

Yan S, Li YZ, Zhu JW, Liu CL, Wang P, Liu YL. Role of CASP-8 and FASL polymorphisms in susceptibility to gastric cancer in a Han Chinese population from Northeast China. PLoS ONE. 2020;15(5):e0232882. https://doi.org/10.1371/journal.pone.0232882.

Article  CAS  Google Scholar 

Annuar AA, Nailon WH, McLaughlin SJ, Murray GI, Gilbert FJ. The functional polymorphism of FasL (TNFSF6)-844T > C is associated with grade and stage of primary colorectal cancer. Oncol Rep. 2021;45(3):1083–91. https://doi.org/10.3892/or.2021.7934.

Article  CAS  Google Scholar 

El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–e12731. https://doi.org/10.1053/j.gastro.2011.12.061.

Article  PubMed  Google Scholar 

Elbrolosy AM, Algarni AA, Alenezi SA, Albalawi AE, Ibrahim NK. Association of Fas– 670A > G and FasL– 844T > C polymorphisms with susceptibility to hepatitis C virus infection and treatment response. J Med Virol. 2023;95(1):e28107. https://doi.org/10.1002/jmv.28107.

Article  CAS  Google Scholar 

Dietrich CF, Kramer H, Geyer T. The role of fas/fasl signaling in chronic liver diseases. Liver Int. 2016;36(8):1231–40. https://doi.org/10.1111/liv.13125.

Article  CAS  Google Scholar 

Loomba R, Adams LA, Sanyal AJ. Genetic determinants of disease progression in nonalcoholic fatty liver disease. Hepatology. 2021;73(4):1607–19. https://doi.org/10.1002/hep.31591.

Article  Google Scholar 

Chen QY, Xue HB, Zhang ML, Guan F, Zhang JH, Li TR, et al. Fas gene polymorphisms, alcohol consumption and the risk of liver cirrhosis: a case-control study in Chinese Han population. J Gastroenterol Hepatol. 2022;37(4):743–51. https://doi.org/10.1111/jgh.15759.

Article  Google Scholar 

Wang C, Zhang X, Yang F, Ren H, Wu D, Wang J, et al. FasL promoter polymorphism is associated with hepatocellular carcinoma risk in interaction with hepatitis B virus infection. Hepatol Res. 2020;50(3):391–402. https://doi.org/10.1111/hepr.13460.

Article  CAS  Google Scholar 

Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2010;59(11):1410–9. https://doi.org/10.1136/gut.2009.191353.

Article  Google Scholar 

Cheng J, Wang Y, Zhang X, Liu Z, Yang H, Li B. Genetic variations in Fas and FasL genes and their impact on hepatocyte apoptosis in liver cirrhosis development. J Hepatol. 2024;81(3):578–89. https://doi.org/10.1016/j.jhep.2023.11.028.

Article  CAS  Google Scholar 

Eslami L, Najafizadeh M, Sadeghizadeh M, Zali MR. Association of Fas and FasL gene polymorphisms with the risk of colorectal cancer in Iranian population. J Gastrointest Oncol. 2021;12(4):1478–86.